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Abstract 
Sheep suffer from pain during various husbandry practices as well as during injury or 
diseases such as footrot. This pain could be potentially minimised with the use of analgesics 
such as non-steroidal anti-inflammatory drugs (NSAID). Unfortunately, there are very few 
registered NSAIDs for sheep. Thus, registered analgesics for cattle, for instance ketoprofen 
and meloxicam are used in sheep. Again, the high cost of analgesics and associated potential 
side effects such as reduced fertility, gastric irritation, gastric ulcers etc. evident in other 
species usually limits their use in sheep. Fear of residues in meat may stop some farmers 
from using analgesics. Considering these problems, this study was designed as a groundwork 
to explore a possible and potential use of natural, inexpensive analgesic for sheep. 
Salicylic acid, a derivative of salicin, is a NSAID used effectively in humans as an analgesic 
since ancient times in the form of willow bark and leaves. During this research study, the 
pharmacokinetics of salicylic acid in sheep was analysed after administration of the sodium 
salt of salicylic acid (sodium salicylate/NaS) intravenously and orally at different dose rates. 
The analgesic efficacy of salicylic acid in sheep was also studied after administration of 
sodium salicylate at different dose rates by measuring mechanical and thermal nociceptive 
thresholds. The minimum therapeutic plasma concentration of salicylic acid for analgesia in 
sheep ranged from 25 to 30 μg/mL, which was achieved for about 30 minutes by a 200 mg/kg 
intravenous dose of NaS. During this study it was discovered that thermal nociceptive 
threshold testing is unable to detect any analgesia from salicylic acid and ketoprofen in 
sheep. However, mechanical nociceptive threshold testing efficiently detected the analgesic 
effects of salicylic acid and the positive control, ketoprofen. 
The seasonal variation of willow salicin content (principal precursor of salicylic acid in 
willow) was studied over a year. The salicin in willows in New Zealand is higher during the 
summer months as compared to the winter months of the year, and appears greater in areas 
subject to drought. The analgesic efficacy of willow leaves can be assessed by feeding the 
willow leaves to lame sheep as they readily eat willow leaves. However, to assess the 
analgesia produced by willow in sheep, further research is warranted. 
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